Vaxneuvance

Vaxneuvance is a 15‑valent pneumococcal polysaccharide conjugate vaccine developed to help protect against invasive disease and respiratory infections caused by the bacterium Streptococcus pneumoniae. This vaccine contains purified capsular polysaccharides from 15 different pneumococcal serotypes — including 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F — each individually linked (conjugated) to a carrier protein known as CRM197 to boost immune recognition. The addition of serotypes such as 22F and 33F enhances coverage beyond earlier conjugate vaccines.
The conjugation process helps the immune system recognise polysaccharide components of the bacterial capsule, which in turn supports the production of targeted antibodies. These antibodies can help the body identify and neutralise pneumococcal bacteria if encountered later, thereby reducing the risk of serious complications such as bacteremia (blood infection), meningitis (brain and spinal cord membrane infection), and pneumonia (lung infection).
Vaxneuvance is typically given as an injection into muscle, with dosing and schedules varying by age and health guidelines. It is approved for use in individuals 6 weeks of age and older, making it suitable for both pediatric and adult support.
Common responses following Vaxneuvance administration may include temporary injection site discomfort, redness, swelling, or fatigue, reflecting the activation of the immune system. These responses are generally mild and short‑lived. The vaccine does not protect against pneumococcal serotypes not included in the formulation, so it’s focused specifically on the bacterial variants it contains.
By teaching the immune system to recognise key components of common pneumococcal strains, Vaxneuvance offers broad support against serious pneumococcal infections when integrated with routine health strategies and preventive care.